Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Sanjay Ram and Jutamas Shaughnessy.
Sanjay Ram
Connection Strength
6.128
Jutamas Shaughnessy
  1. Shaughnessy J, Chabeda A, Lewis LA, Ram S. Alternative pathway amplification and infections. Immunol Rev. 2023 01; 313(1):162-180.
    View in: PubMed
    Score: 0.845
  2. Shaughnessy J, Chabeda A, Tran Y, Zheng B, Nowak N, Steffens C, DeOliveira RB, Gulati S, Lewis LA, Maclean J, Moss JA, Wycoff KL, Ram S. An optimized Factor H-Fc fusion protein against multidrug-resistant Neisseria gonorrhoeae. Front Immunol. 2022; 13:975676.
    View in: PubMed
    Score: 0.834
  3. Shaughnessy J, Tran Y, Zheng B, DeOliveira RB, Gulati S, Song WC, Maclean JM, Wycoff KL, Ram S. Development of Complement Factor H-Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-Resistant Neisseria gonorrhoeae. Front Immunol. 2020; 11:583305.
    View in: PubMed
    Score: 0.734
  4. Shaughnessy J, Lewis LA, Zheng B, Carr C, Bass I, Gulati S, DeOliveira RB, Gose S, Reed GW, Botto M, Rice PA, Ram S. Human Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against Neisseria gonorrhoeae. J Immunol. 2018 11 01; 201(9):2700-2709.
    View in: PubMed
    Score: 0.635
  5. Shaughnessy J, Gulati S, Agarwal S, Unemo M, Ohnishi M, Su XH, Monks BG, Visintin A, Madico G, Lewis LA, Golenbock DT, Reed GW, Rice PA, Ram S. A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol. 2016 Feb 15; 196(4):1732-40.
    View in: PubMed
    Score: 0.527
  6. Shaughnessy J, Vu DM, Punjabi R, Serra-Pladevall J, DeOliveira RB, Granoff DM, Ram S. Fusion protein comprising factor H domains 6 and 7 and human IgG1 Fc as an antibacterial immunotherapeutic. Clin Vaccine Immunol. 2014 Oct; 21(10):1452-9.
    View in: PubMed
    Score: 0.478
  7. Shaughnessy J, Lewis LA, Jarva H, Ram S. Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun. 2009 May; 77(5):2094-103.
    View in: PubMed
    Score: 0.328
  8. Gulati S, Mattsson AH, Schussek S, Zheng B, DeOliveira RB, Shaughnessy J, Lewis LA, Rice PA, Comstedt P, Ram S. Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence. mBio. 2023 Dec 19; 14(6):e0250023.
    View in: PubMed
    Score: 0.226
  9. Gulati S, Beurskens FJ, de Kreuk BJ, Roza M, Zheng B, DeOliveira RB, Shaughnessy J, Nowak NA, Taylor RP, Botto M, He X, Ingalls RR, Woodruff TM, Song WC, Schuurman J, Rice PA, Ram S. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLoS Biol. 2019 06; 17(6):e3000323.
    View in: PubMed
    Score: 0.167
  10. Shaughnessy J, Ram S, Rice PA. Biology of the Gonococcus: Disease and Pathogenesis. Methods Mol Biol. 2019; 1997:1-27.
    View in: PubMed
    Score: 0.162
  11. Ram S, Shaughnessy J, de Oliveira RB, Lewis LA, Gulati S, Rice PA. Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics. Pathog Dis. 2017 06 01; 75(4).
    View in: PubMed
    Score: 0.145
  12. Ram S, Shaughnessy J, DeOliveira RB, Lewis LA, Gulati S, Rice PA. Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology. 2016 10; 221(10):1110-23.
    View in: PubMed
    Score: 0.135
  13. Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio. 2013 Oct 15; 4(5):e00339-13.
    View in: PubMed
    Score: 0.113
  14. Shaughnessy J, Ram S, Bhattacharjee A, Pedrosa J, Tran C, Horvath G, Monks B, Visintin A, Jokiranta TS, Rice PA. Molecular characterization of the interaction between sialylated Neisseria gonorrhoeae and factor H. J Biol Chem. 2011 Jun 24; 286(25):22235-42.
    View in: PubMed
    Score: 0.095
  15. Beernink PT, Di Carluccio C, Marchetti R, Cerofolini L, Carillo S, Cangiano A, Cowieson N, Bones J, Molinaro A, Paduano L, Fragai M, Beernink BP, Gulati S, Shaughnessy J, Rice PA, Ram S, Silipo A. Gonococcal Mimitope Vaccine Candidate Forms a Beta-Hairpin Turn and Binds Hydrophobically to a Therapeutic Monoclonal Antibody. JACS Au. 2024 Jul 22; 4(7):2617-2629.
    View in: PubMed
    Score: 0.059
  16. Peterson SL, Krishnan A, Patel D, Khanehzar A, Lad A, Shaughnessy J, Ram S, Callanan D, Kunimoto D, Genead MA, Tolentino MJ. PolySialic Acid Nanoparticles Actuate Complement-Factor-H-Mediated Inhibition of the Alternative Complement Pathway: A Safer Potential Therapy for Age-Related Macular Degeneration. Pharmaceuticals (Basel). 2024 Apr 17; 17(4).
    View in: PubMed
    Score: 0.058
  17. Foss S, Sakya SA, Aguinagalde L, Lustig M, Shaughnessy J, Cruz AR, Scheepmaker L, Mathiesen L, Ruso-Julve F, Anthi AK, Gj?lberg TT, Mester S, Bern M, Evers M, Bratlie DB, Michaelsen TE, Schlothauer T, Sok D, Bhattacharya J, Leusen J, Valerius T, Ram S, Rooijakkers SHM, Sandlie I, Andersen JT. Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. Nat Commun. 2024 Mar 07; 15(1):2007.
    View in: PubMed
    Score: 0.058
  18. Menon SS, Ramirez-Toloza G, Wycoff KL, Ehinger S, Shaughnessy J, Ram S, Ferreira VP. Mechanisms by which Factor H protects Trypanosoma cruzi from the alternative pathway of complement. Front Immunol. 2024; 15:1152000.
    View in: PubMed
    Score: 0.058
  19. Bettoni S, Shaughnessy J, Maziarz K, Ermert D, Gulati S, Zheng B, M?rgelin M, Jacobsson S, Riesbeck K, Unemo M, Ram S, Blom AM. C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections. JCI Insight. 2019 12 05; 4(23).
    View in: PubMed
    Score: 0.043
  20. Gulati S, Pennington MW, Czerwinski A, Carter D, Zheng B, Nowak NA, DeOliveira RB, Shaughnessy J, Reed GW, Ram S, Rice PA. Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine. mBio. 2019 11 05; 10(6).
    View in: PubMed
    Score: 0.043
  21. Gulati S, Shaughnessy J, Ram S, Rice PA. Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine. Front Immunol. 2019; 10:321.
    View in: PubMed
    Score: 0.041
  22. Kenno S, Speth C, Rambach G, Binder U, Chatterjee S, Caramalho R, Haas H, Lass-Fl?rl C, Shaughnessy J, Ram S, Gow NAR, Orth-H?ller D, W?rzner R. Candida albicans Factor H Binding Molecule Hgt1p - A Low Glucose-Induced Transmembrane Protein Is Trafficked to the Cell Wall and Impairs Phagocytosis and Killing by Human Neutrophils. Front Microbiol. 2018; 9:3319.
    View in: PubMed
    Score: 0.041
  23. Ermert D, Weckel A, Magda M, M?rgelin M, Shaughnessy J, Rice PA, Bj?rck L, Ram S, Blom AM. Human IgG Increases Virulence of Streptococcus pyogenes through Complement Evasion. J Immunol. 2018 05 15; 200(10):3495-3505.
    View in: PubMed
    Score: 0.038
  24. Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, Visintin A, Monks B, Madico G, Rice PA. Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol. 2008 Mar 01; 180(5):3426-35.
    View in: PubMed
    Score: 0.038
  25. Blom AM, Magda M, Kohl L, Shaughnessy J, Lambris JD, Ram S, Ermert D. Factor H-IgG Chimeric Proteins as a Therapeutic Approach against the Gram-Positive Bacterial Pathogen Streptococcus pyogenes. J Immunol. 2017 12 01; 199(11):3828-3839.
    View in: PubMed
    Score: 0.037
  26. Wong SM, Shaughnessy J, Ram S, Akerley BJ. Defining the Binding Region in Factor H to Develop a Therapeutic Factor H-Fc Fusion Protein against Non-Typeable Haemophilus influenzae. Front Cell Infect Microbiol. 2016; 6:40.
    View in: PubMed
    Score: 0.033
  27. Ermert D, Shaughnessy J, Joeris T, Kaplan J, Pang CJ, Kurt-Jones EA, Rice PA, Ram S, Blom AM. Virulence of Group A Streptococci Is Enhanced by Human Complement Inhibitors. PLoS Pathog. 2015 Jul; 11(7):e1005043.
    View in: PubMed
    Score: 0.032
  28. Beernink PT, Shaughnessy J, Stefek H, Ram S, Granoff DM. Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines. Clin Vaccine Immunol. 2014 Nov; 21(11):1505-11.
    View in: PubMed
    Score: 0.030
  29. Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog. 2012; 8(5):e1002688.
    View in: PubMed
    Score: 0.026
  30. Vu DM, Shaughnessy J, Lewis LA, Ram S, Rice PA, Granoff DM. Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect Immun. 2012 Feb; 80(2):643-50.
    View in: PubMed
    Score: 0.025
  31. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol. 2011 Mar 15; 186(6):3606-14.
    View in: PubMed
    Score: 0.023
  32. Beernink PT, Shaughnessy J, Ram S, Granoff DM. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vaccine Immunol. 2010 Jul; 17(7):1074-8.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.